Andrew Brenyo1, Alon Barsheshet1, Valentina Kutyifa1, Anne-Christine Ruwald1, Mohan Rao1, Wojciech Zareba1, Anne-Catherine Pouleur1, Dorit Knappe1, Scott D Solomon1, Scott McNitt1, David T Huang1, Arthur J Moss1, Ilan Goldenberg2. 1. From the Cardiology Division of the Department of Medicine, University of Rochester Medical Center, NY (A. Brenyo, V.K., A.-C.R., M.R., W.Z., D.T.H., A.J.M., I.G., S.M.); Department of Cardiology, Greenville University Health System, SC (A. Brenyo); Department of Cardiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (A.-C.P., D.K., S.D.S.); Cardiology Department, Rabin Medical Center, Petah Tikva, Israel (A. Barsheshet); and Department of Cardiology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel (A. Barsheshet). 2. From the Cardiology Division of the Department of Medicine, University of Rochester Medical Center, NY (A. Brenyo, V.K., A.-C.R., M.R., W.Z., D.T.H., A.J.M., I.G., S.M.); Department of Cardiology, Greenville University Health System, SC (A. Brenyo); Department of Cardiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (A.-C.P., D.K., S.D.S.); Cardiology Department, Rabin Medical Center, Petah Tikva, Israel (A. Barsheshet); and Department of Cardiology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel (A. Barsheshet). ilan.goldenberg@heart.rochester.edu.
Abstract
BACKGROUND: There are limited data regarding factors associated with spontaneous left ventricular reverse remodeling (S-LVRR) among mildly symptomatic heart failure (HF) patients and its prognostic implications on clinical outcomes. METHODS AND RESULTS: Best subsets logistic regression analysis was used to identify factors associated with S-LVRR (defined as ≥15% reduction in left ventricular end-systolic volume at 1-year of follow-up) among 612 patients treated withinternal cardioverter defibrillator-only therapy in Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT) and to create a score for the prediction of S-LVRR. Cox proportional hazards regression modeling was used to assess the clinical outcome of all internal cardioverter defibrillator-only patients (n=714) with a high S-LVRR score. S-LVRR occurred in 25% of internal cardioverter defibrillator-only patients. Predictors of S-LVRR included systolic blood pressure≥140 mm Hg, serum creatinine<1.0 mg/dL, QRS 130 to 160 ms, and nonischemic cardiomyopathy. Multivariate analysis showed that each 1-point increment in S-LVRR score (range, 0-7) was associated with an 11% (P=0.019) reduction in the risk of HF or death. Treatment with cardiac resynchronization therapy was associated with a significant reduction in the risk of HF or death only among internal cardioverter defibrillator-treated patients with a low (Q1-3) S-LVRR score (hazard ratio=0.55; P<0.001), but not among those with a higher (Q4) score (hazard ratio=1.06; P=0.72). CONCLUSIONS: Our data suggest that approximately one quarter of mild HF patients eligible for biventricular pacing experience S-LVRR. Combined assessment of clinical factors associated with S-LVRR can be used to identify mild HF patients with a low risk for clinical events without cardiac resynchronization therapy intervention. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00180271.
RCT Entities:
BACKGROUND: There are limited data regarding factors associated with spontaneous left ventricular reverse remodeling (S-LVRR) among mildly symptomatic heart failure (HF) patients and its prognostic implications on clinical outcomes. METHODS AND RESULTS: Best subsets logistic regression analysis was used to identify factors associated with S-LVRR (defined as ≥15% reduction in left ventricular end-systolic volume at 1-year of follow-up) among 612 patients treated with internal cardioverter defibrillator-only therapy in Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT) and to create a score for the prediction of S-LVRR. Cox proportional hazards regression modeling was used to assess the clinical outcome of all internal cardioverter defibrillator-onlypatients (n=714) with a high S-LVRR score. S-LVRR occurred in 25% of internal cardioverter defibrillator-onlypatients. Predictors of S-LVRR included systolic blood pressure≥140 mm Hg, serum creatinine<1.0 mg/dL, QRS 130 to 160 ms, and nonischemic cardiomyopathy. Multivariate analysis showed that each 1-point increment in S-LVRR score (range, 0-7) was associated with an 11% (P=0.019) reduction in the risk of HF or death. Treatment with cardiac resynchronization therapy was associated with a significant reduction in the risk of HF or death only among internal cardioverter defibrillator-treatedpatients with a low (Q1-3) S-LVRR score (hazard ratio=0.55; P<0.001), but not among those with a higher (Q4) score (hazard ratio=1.06; P=0.72). CONCLUSIONS: Our data suggest that approximately one quarter of mild HF patients eligible for biventricular pacing experience S-LVRR. Combined assessment of clinical factors associated with S-LVRR can be used to identify mild HF patients with a low risk for clinical events without cardiac resynchronization therapy intervention. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00180271.
Authors: Selcuk Adabag; Kristen K Patton; Alfred E Buxton; Thomas S Rector; Kristine E Ensrud; Kairav Vakil; Wayne C Levy; Jeanne E Poole Journal: JAMA Cardiol Date: 2017-07-01 Impact factor: 14.676
Authors: Marco Merlo; Davide Stolfo; Marco Anzini; Francesco Negri; Bruno Pinamonti; Giulia Barbati; Federica Ramani; Andrea Di Lenarda; Gianfranco Sinagra Journal: J Am Heart Assoc Date: 2015-01-13 Impact factor: 5.501
Authors: Paweł Balsam; Krzysztof Ozierański; Agata Tymińska; Renata Główczyńska; Michał Peller; Anna Fojt; Andrzej Cacko; Bartosz Sieradzki; Elwira Bakuła; Maciej Markulis; Robert Kowalik; Zenon Huczek; Krzysztof J Filipiak; Grzegorz Opolski; Marcin Grabowski Journal: Trials Date: 2017-01-23 Impact factor: 2.279
Authors: Carles Díez-López; Joel Salazar-Mendiguchía; Elena García-Romero; Lara Fuentes; Josep Lupón; Antoni Bayés-Genis; Nicolás Manito; Marta de Antonio; Pedro Moliner; Elisabet Zamora; Pablo Catalá-Ruiz; Miguel Caínzos-Achirica; Josep Comín-Colet; José González-Costello Journal: J Cardiovasc Dev Dis Date: 2022-01-11